FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for adults with moderate to severe ulcerative colitis.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The recommended induction dosage is …
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
FDA approves Skyrizi for ulcerative colitis, a new treatment option.
The FDA approved Skyrizi (risankizumab) for moderately to severely active ulcerative colitis in adults. The approval adds to existing indica…
The FDA approved Skyrizi (risankizumab) for adults with moderate to severe ulcerative colitis. It is given as an IV infusion at first, then …
FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica LD for severe nodular acne.
FDA approved Absorica LD (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients aged 12 and older. It is reserved for …
The FDA approved Absorica LD (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with oth…
FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
FDA approves new acne drug Absorica for severe cases
The FDA approved Absorica (isotretinoin) for severe recalcitrant nodular acne in non-pregnant patients 12 years and older. It is reserved fo…
The FDA approved Absorica (isotretinoin) for severe nodular acne in patients 12 and older. It is for those who have not improved with other …
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
Nurses share how trauma care shapes their daily work and personal lives
Fifteen experienced trauma nurses shared their lived experiences managing critical multiple injuries in a tertiary Hunan hospital. Their nar…
Fifteen experienced nurses describe the professional challenges, teamwork dynamics, and stress they face while managing critical trauma case…
FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
FDA approves Tremfya for ulcerative colitis and Crohn's disease.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis and Crohn's disease. The approval exp…
The FDA approved Tremfya (guselkumab) for adults with moderate to severe ulcerative colitis or Crohn's disease. It is the first drug of its …
Early preterm birth linked to lower atopic dermatitis risk in large meta-analysis
Preterm birth linked to lower allergy risk in children
A meta-analysis of observational studies involving over 5 million children found that early preterm birth was associated with a reduced risk…
Babies born early may have lower odds of developing eczema and hay fever, a large analysis finds.
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
All Dermatology Articles
- FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
- FDA Approves Skyrizi (risankizumab) for Ulcerative Colitis in Adults
- FDA Approves Absorica LD (isotretinoin) for Severe Recalcitrant Nodular Acne
- FDA Approves Absorica (isotretinoin) for Severe Recalcitrant Nodular Acne
- Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
- SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
- Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
- FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
- Early preterm birth linked to lower atopic dermatitis risk in large meta-analysis
- ALK fusion Spitz neoplasms show distinct morphologic patterns and genomic correlates in meta-analysis
- Mohs micrographic surgery reduces local recurrence by 12% versus superficial radiation therapy in nonmelanoma skin cancer
- Quantitative PDA improves understanding and confidence versus qualitative PDA in dysplastic nevus screening
- High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
- Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
- Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
- Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
- Real-world meta-analysis of baricitinib for atopic dermatitis shows variable outcomes
- Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
- Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
- Narrative review explores gut microbiota links to atopic dermatitis pathogenesis and potential therapeutic strategies
- Review highlights emerging mechanisms for allergic contact dermatitis management
- FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
- FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
- Marburg MS case shows treatment challenges and fatal outcome
- FDA Approves Siliq (brodalumab) for Moderate to Severe Plaque Psoriasis
- Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
- Narrative review of treatment strategies for primary central nervous system lymphoma
- Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
- Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
- Psoriatic arthritis linked to interstitial lung disease prevalence
- Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
- Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks
- Brodalumab Improves Palmoplantar Pustulosis in Japanese Adults in Phase 3 Trial
- 5-Fluorouracil and MAL-PDT vs Surgery for Bowen's Disease: 4-Year Outcomes
- Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
- Meta-analysis finds early-stage cutaneous angiosarcoma linked to longer survival
- Rapid review and meta-analysis of psychological distress in adults undergoing Mohs micrographic surgery
- Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia
- Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
- Preclinical study shows hydrogel microneedle patches sample microbes and immune cells in humans and mice
- Methodological study evaluates synthetic image framework for melanoma classification accuracy in preprint report
- Imsidolimab shows GPPPGA clearance in generalized pustular psoriasis flare at 4 weeks
- Systematic scoping review shows declining filarial infection prevalence in Latin America from 1946 to 2025
- Surgical excision in dromedary camels yields 83.70% recovery with 16.30% complications across cutaneous and subcutaneous masses
- Genetic burden in PI3K–AKT–mTOR pathway linked to microscopic polyangiitis susceptibility in Chinese cohort
- Stapokibart plus glucocorticoids achieves disease control in elderly bullous pemphigoid patients
- 675-nm Diode Laser as Adjuvant Therapy for Telogen Effluvium: A Retrospective Case Series
- Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
- Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
- Pilot RCT protocol assesses VR-PAT game versus dark screen for pain and anxiety in pediatric laser therapy
- FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
- FDA Approves Cosentyx (secukinumab) for Moderate to Severe Hidradenitis Suppurativa in Adults and Pediatric Patients
- MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study
- Review suggests automated stool management system may reduce costs and nursing time in ICU fecal incontinence
- Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- Review of chronic skin ulcers in Burkina Faso highlights Buruli ulcer prevalence in pediatric patients
- FDA Approves Abreva () for cold sores/fever blisters on the face or lips to shorten healing time and duration of symptoms
- Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
- Systematic review of public health interventions to curb respiratory infections at sporting mass gatherings
- Machine learning and deep learning applications in inguinal hernia care show promise for risk prediction and training
- Atopic constitution associated with severe Mycoplasma pneumoniae pneumonia in children
- Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
- Occupational noise exposure linked to cognitive decline in cross-sectional study of 170 workers
- Retrospective pediatric NTM study finds cervical lymphadenitis predominant, diagnostic delays common
- Phase 2 trial finds topical STS01 1% improves SALT scores in patchy alopecia areata
- Pivekimab sunirine shows activity in frontline and relapsed Blastic plasmacytoid dendritic cell neoplasm
- Network meta-analysis finds biologics superior to placebo for pediatric plaque psoriasis
- Outpatient IV sedation for dental care in special needs patients shows 3.3% minor complication rate
- Narrative review suggests endovascular treatment may be feasible and safe for posterior epistaxis
- Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata
- AI pipeline shows substantial agreement with dermatologists for grading atopic dermatitis erythema severity
- Meta-analysis compares HAQ-DI, SF36-PF, and SF36-PCS for physical function in psoriatic arthritis trials
- Early proactive TCS for infant AD linked to lower food allergy rates at age 3
- PD-L1 expression shows subtype-specific prognostic value in skin neoplasms, meta-analysis finds
- Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
- Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
- Phase 2 trial: Topical STS01 shows dose-related hair regrowth in mild-moderate alopecia areata
- Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
- Smartphone-based wound measurement shows excellent agreement with planimetry in single-center study
- Hair follicle-derived epithelial sheet transplantation shows repigmentation in stable vitiligo patients
- CDC recommends approaches to maintain tuberculin skin testing during expected Aplisol shortage
- Simulation study finds HEPA air cleaners and masking reduce exposure to simulated SARS-CoV-2 aerosols
- Report compares motor vehicle crash death rates across 29 high-income countries
- Case report: Initial positive measles IgM tests in two Samoan children were false positives
- Traffic-related death rates compared between US and 27 other high-income countries
- Report describes emergency department visits for traffic-related pedestrian injuries in the US
- Outbreak of Purpureocillium lilacinum fungal skin infections reported at Washington dermatology clinic
- Chinese APS-1 patients show recurrent AIRE gene deletion, male predominance, and low classic triad incidence
- Review analyzes PANoptosis mechanisms and potential treatments for ischemia-reperfusion injury
- Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
- Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis
- Placebo effect observed in double-blinded food challenges for dogs with atopic dermatitis
- Imiquimod costs substantially less than radiotherapy for lentigo maligna in Australian analysis
- Arthroscopy-assisted curettage and bone grafting for proximal femur giant cell tumor in a 25-year-old man
- Guselkumab Shows Improvement in Inverse Psoriasis in Single Case Report
- Nomogram predicts occupational contact dermatitis risk in Chinese nurses with excellent discrimination
- PFAS mixture exposure shows positive association with serum total IgE levels in Korean adults
- Topical PDE4 inhibitors show efficacy in pediatric atopic dermatitis meta-analysis
- Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
- Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
- Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
- Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
- Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
- Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
- Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks